SMi Group's Biosimilars & Biobetters conference
Upcoming SlideShare
Loading in...5
×
 

SMi Group's Biosimilars & Biobetters conference

on

  • 177 views

SMi Group's 5th annual Biosimilars & Biobetters 2014 conference returns to London this September

SMi Group's 5th annual Biosimilars & Biobetters 2014 conference returns to London this September

Statistics

Views

Total Views
177
Views on SlideShare
177
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

SMi Group's Biosimilars & Biobetters conference SMi Group's Biosimilars & Biobetters conference Document Transcript

  • Benefits of attending: • The must attend event discussing strategies for accelerating biosimilar drug development to market • Explore the latest thinking and techniques in this growing area • Book now and join us for exciting interactive discussions about the current and potential offerings for biosimilar production • Hear from knowledgeable presenters – our expert panel of speakers are handpicked! • The ideal platform for networking and learning from your industry peers PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS Wednesday 1st October 2014, Holiday Inn Regents Park Hotel, London A: Biosimilars - A Regulatory Update Workshop Leader: Dr Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi Headquarters 8.30am - 12.30pm B: Biosimilars - ‘The Holy Grail?’ Workshop Leader: Ineke Braat, Chief Executive Officer, PanGenrika 1.30pm – 5.30pm Chairperson: Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals Key Speakers Include: • Dr Uwe Gudat, Head of Safety Biosimilars, Merck • Catherine Akers, Regulatory Affairs Manager, Amgen • Steiner Madsen, Medical Director, Department of Drug Information, Norwegian Medicines Agency • Dr Alok Sharma, Principal Scientist & Head Analytical Development, Lupin Limited • Alan Sheppard, Principal Global Head Generics, Thought Leadership, IMS Health, UK • Victoria Fine, Founder, Psoriasense …Look inside for further details! SMi present the 5th annual… 29th - 30th SEPT 2014Holiday Inn Regents Park Hotel, London The biosimilars opportunity: creating and commercialising a quality product Biosimilars & Biobetters BOOK BY 30TH MAY AND SAVE £300 • BOOK BY 30TH JUNE AND SAVE £100 www.biosimilars-biobetters.co.uk Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 ACADEMIC & GROUPS DISCOUNTS AVAILABLE @SMIPHARM Sponsored by:
  • Register online at: www.biosimilars-biobetters.co.uk • Alternatively fa Biosimilars & Biobetters Conference Day One I Monday 29th September 2014 8.30 Registration & Coffee 9.00 Chairman’s Opening Remarks Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals MARKET OUTLOOK - PART I OPENING ADDRESS 9.10 What is on the horizon? ... reviewing the opportunities and challenges for the biopharmaceutical industry • Reviewing the sustainability of the biosimilars market, will it be saturated in the future? • The big question…who will be most successful, those who are: - the fastest to market - generates the most similar biosimilar • Evaluating the barriers to market entry and uptake for biosimilars • Where are we heading and what needs to happen? Alan Sheppard, Principal Global Head Generics, Thought Leadership, IMS Health, UK 9.50 The gloves are off! Measuring the viability of biosimilars vs. biobetters • What is the point of a biosimilar, why not go for a biobetter? • Where are biobetters being used and are they indeed better? • What is a biobetter anyway, and what is the relevant regulatory framework? Paul Ashton, President & Chief Executive Officer, pSivida 10.30 Morning Coffee 10.50 The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry • Understanding how this will shape the competitive, dynamic and commercially lucrative biosimilars market segment • Reviewing why big pharma companies are considering entering the market with monoclonal antibody biosimilars • Will their experience in marketing, manufacturing skills and industry knowledge give them a competitive advantage over those already in the market? • What are their weaknesses? Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals 11.30 Biosimilars, biobetters - the patients perspective • A patients understanding of biologics, biobetters & biosimilars • What biosimilars and biobetters actually mean to patients • The true impact of biosimilars and biobetters Victoria Fine, Founder, Psoriasense 12.10 Networking lunch REGULATORY UPDATES 1.10 Biosimilars/ Biobetters in the USA • US PTO regulations extending the impact of the Myriad decision • Strategy and hurdles for patenting your biosimilar in the US • Update on evolving FDA regulations for biosimilars: why are there no approvals in the US? Albin (Jim) Nelson, Partner, Schwegman, Lundberg, Woessner IP, P.A Robin Chadwick, Partner, Schwegman, Lundberg, Woessner IP, P.A 1.50 Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars • Taking an in-depth look at the discussion regarding the WHOs initiative for a unique identifier for biologics – what will this mean? • The use of identical INNs for biosimilars could lead to inadvertent switching at the pharmacy - true or false? • What is the view at home and abroad? • USA - GphA and originator citizen petitions to the FDA Peter Wittner, Senior Consultant, Interpharm Consultancy 2.30 You can’t injunct me - I’m a biosimilar! • Review of the principles governing interim injunctions in patent litigation • Application of those principles to pharma cases • Why biosimilar cases may not necessarily be a good fit – will the injunctions stick?  Dominic Adair, Associate, Bristows 3.10 Afternoon Tea 3.30 European update - the latest in regulatory thinking • Understanding current regulatory approval standards for biosimilars in Europe, reviewing the regulatory pathways in other jurisdictions • What are the regulatory requirements for non-clinical studies in developing biosimilars • Other aspects of the regulatory framework to consider when preparing a marketing authorisation application Sarah Faircliffe, Legal Director, Bird & Bird Liz Fuller, Partner, Bird & Bird 4.10 The case for biosimilars - a payer’s perspective • Why are payers interested in utilizing biosimilars? • Switching or not switching in pharmacies? • Switching or not switching for economical reasons after treatment initiation/during treatment? • What will happen in Norway onwards? Erik A. Stene, Senior Advisor/MPhil Econ, Department for pharmacoeconomics/reimbursement/value assessment, Norwegian Medicines Agency 4.50 Same, similar, equivalent, this is a serious game! Proving that a biosimilar is ‘similar’ to the originator is not trivial pursuit! • Defining biosimilarity • How similar is the biosimilar to the innovator…measuring how much work this entails at the early stage • Evaluating what metrics and analytical similarity assessments should be employed when designing a biosimilar development program • Determining type and volume of clinical data required for establishing biosimilarity • Establishing validated standardized assays that allow direct comparisons of the relative potency and immunogenicity of the biosimilar and the innovator product • Considering the limitations of conventional biological assays that may be inadequate to detect differences resulting from a change in the manufacturing process • Conducting a non-clinical or a clinical study Michael Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan 5.30 Chairman’s Closing Remarks and Close of Day One Supplying the following bioproducts to research and industry: Albumins, Disease state serum, Human and animal sera for cell culture and diagnostic reagents. Human and animal Immunoglobulin’s. Fluorescent conjugates for Flow Cytometry, HTS and Multiplexing. GLYKO and GlykoPrep products for glycan profiling. Raw materials for Diagnostic reagent manufacturers of Clinical chemistry and ELISA’s. www.europa-bioproducts.com Schwegman Lundberg & Woessner was founded in 1993 with a commitment to innovation. Today, SLW has offices in Minneapolis, Silicon Valley, and Texas as well as attorneys in New York City, Washington DC, and San Diego. SLW has over 100 attorneys with advanced degrees in the areas of organic chemistry, molecular biology, genetics, biochemistry and other life sciences as well as chemical and mechanical engineering, electrical, computer/software. www.slwip.com Sponsored by
  • ax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Biosimilars & Biobetters Conference Day Two I Tuesday 30th September 2014 8.30 Registration & Coffee 9.00 Chairman’s Opening Remarks Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals MARKET OUTLOOK - PART II OPENING ADDRESS 9.10 Biosimilars - hurdles to patients’ access • Development of biosimilars: A case study • Patent protection • INN issue • Switching: interchangeability and substitution Dr Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi Headquarters 9.50 What do they really think...reviewing customer perceptions of biosimilars in Europe • Discussing what doctors think of biosimilars and how willing are they to prescribe them • Monitoring how patients react when their doctor prescribes a biosimilar • Are payors pushing for more utilization of biosimilars in Europe? Ineke Braat, Chief Executive Officer, PanGenerika 10.30 Morning Coffee 10.50 Innovations in creating best in class biosuperior biologics: meeting the challenges of biosimilars • Innovations in improving the existing biologics therapies to create best in class molecules for diseases with unmet medical needs • Making biosuperiors successful and cost effective through advances in protein engineering and pioneering technologies - Case studies of biosuperior vs. biosimilars • Identifying which class of biologics have the best potential for ‘biosuperior’ development • Challenges in development of biosuperior biologics • Accelerated preclinical and clinical development of biosuperior biologics Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, Medimmune (AstraZeneca Biologics) BIOSIMILAR DEVELOPMENTS 11.30 Pharmacovigilance considerations for biologics and biosimilars • Unique characteristics for biologics which influence their safety profile • Importance for accurate traceability to allow effective pharmacovigilance • How biologics have been recognised in the new EU pharmacovigilance legislation and what implementation looks like across Europe. Catherine Akers, Regulatory Affairs Manager, Amgen 12.10 Networking lunch 1.10 Tracking the introduction of biosimilar infliximab in Norway • What are the attitudes of physicians? • Switching study – what is the status? • Monitoring prices and sales Steinar Madsen, Medical Director, Norwegian Medicines Agency 1.50 Designing and executing comparability studies…an important ‘key’ in the development of products • Conducting meaningful preclinical and clinical comparability studies, to establish analytical and bioanalytical equivalency between biosimilars and originators • Ensuring a comparability exercise is followed with the innovator product at all levels of product development, including: - physicochemical attributes - biological activity - preclinical in vivo comparability - Phase I PK and safety - Phase III efficacy and safety • Demonstrating equivalence to materials used in toxicology and early phase clinical trials to avoid bridging studies which increase timescales and costs • Guidance on how to practically carry out comparability studies and prove comparability to regulators Dr Alok Sharma, Principal Scientist & Head Analytical Development, Lupin Limited 2.30 Afternoon Tea 2.50 A clinical perspective on biosimilars: development and beyond • The challenge - creating strategies to overcome the obstacles we face • The means - utilizing the tools at our disposal • The scenarios - a collection of possible outcomes Dr Uwe Gudat, Head of Safety Biosimilars, Merck 3.30 A new dawn… biosimilar monoclonal antibodies (mAbs), a new milestone for the biosimilar market! • Reviewing how approval of the first biosimilar monoclonal antibody therapy will impact the industry, what are the implications for 2014 and beyond • Evaluating if this will spearhead the start of a new era of mAbs in the pharma industry • Discussing how to get regulatory approval for your mAb • Will this bring greater commercial rewards • Will generic companies continue to dominate, or can Big Pharma gain control with its huge marketing muscle? Carsten Brockmeyer, Chief Executive Officer, Formycon AG 4.10 Chairman’s Closing Remarks and Close of Day Two Supported by
  • Overview of workshop: Europe is by far the most advanced region with a regulatory pathway for biosimilars for the last decade. This workshop will give a regulatory overview of the biosimilars rules & guidelines in the EU, US and India. This will address the differences between regulatory agencies’ approaches, helping participants build adequate regulatory strategies. Why you should attend: This Workshop will give a detailed overview of the current regulatory situation, current regulatory requirements and address the differences. It will help you to build adequate regulatory strategies to respond to the needs of early access to biosimilars. Programme: 8.30 Registration and coffee 9.00 Opening remarks 9.10 Session 1: Regulatory Overview EU and US: An update on the EU and US regulatory requirements for biosimilars 9.50 Session 2: EU and US Regulatory pathways: A refreshment of the current regulatory pathways for biosimilars in the EU and USA 10.30 Coffee break 11.00 Session 3: Biosimilars Regulatory Overview in India: A description of the regulatory requirement in India and the published biosimilars  guidelines 11.40 Session 4: Biosimilars Wrap-up. Questions and answers, allowing the workshop participants to interact and exchange experiences 12.20 Closing remarks 12.30 End of workshop  About the workshop host: Dr. Michel Mikhail has more than 25 years pharmaceutical industry experience and a track record of achievement in R & D and International Regulatory Affairs in large multinational research-based pharmaceutical companies, as well as in the generic industry. Dr Mikhail is a chartered expert in pharmacology -toxicology, a chartered clinical expert as well as a chartered analytical expert. Dr Mikhail served on the Safety Working Group and Efficacy Working Group of the European Federation of Pharmaceutical Industry Associations (EFPIA) also as a topic leader. He served on the regulatory group of the European branch of the Pharmaceutical Research and Manufacturers of America (PhRMA Europe), on the Regulatory and Scientific Affairs Group of the European Generic Medicines Association (EGA), as well as Pharmacovigilance Working Group, Market Access Advisory Committee, among others and on different associations and organisations. Dr Mikhail is member of the EGA’s European Biosmilars Group (EBG). Dr Mikhail is a Board Member of The European Generic Medicines Association (EGA) as well as member of the Executive Committee of the EGA. He is a member of the British Institute of Regulatory Affairs (BIRA), the European Society of Regulatory Affairs (ESRA), both now known as The Organisation for Professionals in Regulatory Affairs (TOPRA). Dr Mikhail is member of the Expert Committee for Toxicology of the United States Pharmacopea (USP). Dr. Mikhail has been recently nominated as a Member of the Expert Committee of the German Federal Institute of Risk Assessment (Bundesinstitut für Risikobewertung). Currently Dr. Mikhail is Chief Regulatory Officer & Executive Vice President Global Regulatory – Governmental Relations at Fresenius Kabi, a multinational pharmaceutical company. Biosimilars - A Regulatory Update Workshop Leader: Dr Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi Headquarters HALF-DAY POST-CONFERENCE WORKSHOP A Wednesday 1st October 2014 I 8.30am – 12.30pm Holiday Inn Regents Park Hotel, London
  • Overview of workshop: Are biosimilars something that companies should want to introduce in their product portfolio or should we look at other opportunities and leave the bios to companies that have money to burn? That is the big question! Why you should attend: If you want to gain some insight into the costs and profitabiity of biosimilars and and biobetters. Also, if you want to know whether or not you are missing the boat if you don’t get into these products then join this workshop to find out what is happening in this area. Programme: 1.30 Registration and coffee 2.00 Opening remarks 2.10 Session 1: Question you should ask within your organisation before starting to produce biosimilars 2.50 Session 2: Biosimilars what is the ROI for working with them? 3.30 Coffee break 4.00 Session 3: Why and more important; how do you introduce biosimilars 4.40 Session 4: Is there a yellow brick road? 5.20 Closing remarks 5.30 End of workshop  About the workshop host: Ineke Braat, CEO of PanGenerika has been working in the pharmaceutical industry for over 30 years and is founder and owner of PanGenerika B.V., B-Medical B.V. and Sanare B.V, with all companies working within the pharmaceutical and or personal care industry. Ineke has worked in the ‘innovating’ pharmaceutical industry (Abott; Yamanouchi e.a.) before starting her own companies. Ineke’s main focus in all companies is the question: will it benefit the patient/consumer?’ About PanGenerika: PanGenerika began as an alliance of small/medium sized European pharmaceutical companies, but is expanding to all countries that accept e-CTD formatted dossiers. There is only one exclusive member per country. For information please visit www.pangenerika.eu Biosimilars - ‘The Holy Grail?’ Workshop Leader: Ineke Braat, Chief Executive Officer, PanGenrika HALF-DAY POST-CONFERENCE WORKSHOP B Wednesday 1st October 2014 I 1.30pm – 5.30pm Holiday Inn Regents Park Hotel, London, UK Want to know how you can get involved? Interested in promoting your services to this market? Contact Julia Rotar, SMi Marketing on +44 20 7827 6088, or email: jrotar@smi-online.co.uk SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick, Director on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
  • FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk BIOSIMILARS & BIOBETTERS CONFERENCE Conference: Monday 29th – Tuesday 30th September 2014, Holiday Inn Regents Park Hotel, London I Workshops: Wednesday 1st October 2014 4 WAYS TO REGISTER ONLINE www.biosimilars-biobetters.co.uk Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi- online.co.ukorvisitourwebsitewww.smi-online.co.uk/updatesquotingtheURNasdetailedabove your address on the attached letter. Unique Reference Number Our Reference P-117 Terms and Conditions of Booking DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: Department/Division: Company/Organisation: Email: Company VAT Number: Address: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Mobile: Switchboard: Signature: Date: I agree to be bound by SMi’s Terms and Conditions of Booking. ACCOUNTS DEPT Title: Forename: Surname: Email: Address (if different from above): Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: □ Book by 30th May to receive £300 off the conference price □ Book by 30th June to receive £100 off the conference price EARLY BIRD DISCOUNT VENUE Holiday Inn Regent’s Park, Carburton St, London, W1W 5EE DELEGATE DETAILS □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 CONFERENCE PRICES GROUP DISCOUNTS AVAILABLE I would like to attend: (Please tick as appropriate) Fee Total □ Conference & 2 Workshops £2697.00 + VAT £3236.40 □ Conference & 1 Workshop £2098.00 + VAT £2517.60 □ Conference only £1499.00 + VAT £1798.80 □ 1 Workshop only £599.00 + VAT £718.80 □ 2 Workshops only £1198.00 + VAT £1437.60 Workshop A □ Workshop B □ PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80 The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference. Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-117 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 □ Cheque We can only accept Sterling cheques drawn on a UK bank. □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. Card No: □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Cardholder’s Name: Signature: Date: I agree to be bound by SMi’s Terms and Conditions of Booking. Card Billing Address (If different from above): LIVE STREAMING/ON DEMAND/DOCUMENTATION Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room? Price Total □ Live Streaming £999.00 + VAT £1198.80 □ On demand £599.00 + VAT £718.80 (available 24 hours after the event) □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations – paper copy £499.00 - £499.00 (or only £300 if ordered with the Document Portal) PAYMENT VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live Streaming, on Demand, Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here